On August 27, Illuminera, together with Siqi Circle, successfully hosted the Healthcare Consumerization Track at the 11th MMC Medical Market Annual Conference. The track brought together pharmaceutical company representatives, industry experts and ecosystem partners to discuss the evolution of commercialization models and emerging opportunities for out-of-hospital growth in the era of Healthcare Consumerization 2.0.
The Era of Healthcare Consumerization 2.0 Has Arrived
As China’s pharmaceutical market enters a stage of structural growth, the rapid development of out-of-hospital channels, the growing role of patients in decision-making, and the continuous improvement of the regulatory system have made healthcare consumerization more than a new growth direction for pharmaceutical companies. It has become a defining theme in the evolution of future commercialization capabilities.
Lucy Wang, Director of Management Consulting and Consumer Research at IQVIA, noted that future market growth will increasingly come from innovative products, new channels, and more segmented patient groups and scenarios. At the same time, the traditional HCP-centric marketing model is undergoing profound change, with patients shifting from “passive recipients” to “active decision-makers”. Pharmaceutical companies therefore need to move beyond a product-centric focus and further build capabilities in patient insights, patient management, and end-to-end commercialization.
Kaya Zhang, Associate Director of cbh at Illuminera, shared the “three key consumer-facing growth engines” across the pharmaceutical product lifecycle. She proposed that channel consumerization, content consumerization, and patient management consumerization are becoming important levers for pharmaceutical companies to rebuild their growth systems. Companies need to re-examine the patient journey and extend the traditional “diagnosis and treatment pathway” to cover the entire process of decision-making, drug purchase, medication use, and long-term management.
From Patients to Products: The Competitive Landscape for Out-of-Hospital Growth Is Shifting
In recent years, the out-of-hospital market has continued to grow, while patient decision-making has become increasingly complex. Moderated by Aaron Guo, Director of cbh at Illuminera, the roundtable was titled “From Patients to Products: How Healthcare Consumerization Is Reshaping Growth Pathways for Pharma Companies.” Panelists included Daniel Han, Vice President of Consumer Marketing Management Center at Innovent Biologics; Grace Chen, Pharmaceutical Account Lead for the O2O Channel at Meituan Medicine; and Leon Zhang, Head of Digital Marketing Solutions at JD Health.
The discussion explored in depth the growth drivers of the out-of-hospital market, changes in patient behavior, To-C practice exploration, and the future competitive landscape. Looking ahead, success in the out-of-hospital market will increasingly depend on strengthening patient awareness, building brand preference, and creating sustainable long-term patient value.
From Targeted Activation to Impact Validation: Unlocking Patient-Led Growth
Faced with an increasingly complex patient decision journey, precise activation and robust impact measurement have become key to growth. Kevin Cai, Director of cbh at Illuminera, introduced the concept of the “Bullseye Audience”. He noted that the focus of new drug launches and patient activation is no longer about maximizing reach, but about identifying and engaging the patients who matter most. Through deep insights into the patient journey, decision-making patterns, and unmet needs, companies can build a precise activation system that is “reachable, convertible, and verifiable”, upgrading from broad communication to precision patient engagement.
To address the challenges of measuring and evaluating patient education impact, Chloe Wei, Senior Manager of cbh at Illuminera, noted that as patient education enters the omni-channel era, companies need to integrate and analyze three types of data: patient awareness and mindset, public-domain behavioral pathways, and channel business performance. This enables the establishment of an end-to-end evaluation system, allowing patient education to become truly measurable in impact, optimizable in investment, and verifiable in value.
The Rise of Instant Retail Channels Is Reshaping the New Ecosystem for Out-of-Hospital Growth
Against the backdrop of the continued expansion of the out-of-hospital market, channel value is also being redefined. Grace Chen, Pharmaceutical Account Lead for the O2O Channel at Meituan Medicine, shared that instant retail is evolving from a fulfillment channel into a comprehensive health services ecosystem. User needs have expanded from disease treatment to broader health scenarios such as sleep, weight management, and family health management. Channel innovation and scenario-based applications are accelerating the reshaping of the out-of-hospital growth ecosystem. In the future, pharmaceutical companies will need to build an integrated growth model spanning reach, education, service, and conversion.
END
In the era of Healthcare Consumerization 2.0, sustainable growth will depend not on reaching more patients, but on deeply understanding patient needs, effectively managing the patient journey, and translating those insights into measurable business outcomes.
Illuminera will continue to leverage its dual expertise across consumer goods and healthcare, together with its multi-source data and insight capabilities, to provide pharmaceutical companies with end-to-end solutions spanning brand strategy, patient activation, channel innovation, patient lifecycle management, and marketing effectiveness measurement.
By helping companies translate patient insights into actionable strategies, Illuminera will continue to partner with industry stakeholders to explore new growth pathways in the era of Healthcare Consumerization 2.0.
For more relevant information, please send an email to marketing@illuminera.com.
